Nasus Pharma Ltd (NSRX)
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Nasus Pharma Ltd.
NYSE:NSRXHealthcare · Medical - Pharmaceuticals
+0.00%$3.49
Mkt Cap$40.88M
Float6.56M
O/S11.71M
Inst Own18.4%
SI1.2%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$5.86M
Total Assets$5M
Free Cash Flow-$4.93M
Debt & Equity
Debt 4%
Equity 96%
Total Debt$118K
Total Equity$2.77M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in NSRX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$5M
Liabilities$2.24M
Accounts Receivable$0
Accounts Payable$829K
Inventory$0
PP&E (Net)$149K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - |
| Research and Development | $2.24M | $335K | $567K | $1.12M |
| Selling, General, and Administrative | $2.67M | $743K | $580K | $926K |
| Other | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $4.9M | $1.08M | $1.15M | $2.04M |
| Operating Income (EBIT) | -$4.9M | -$1.08M | -$1.15M | -$2.04M |
| Operating Margin | - | - | - | - |
| Interest Expense | $0 | $29K | $49K | $18K |
| Interest Income | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$901K | -$474K | $142K | -$110K |
| Income Before Tax (EBT) | -$5.8M | -$1.55M | -$1M | -$2.15M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5.86M | -$1.53M | -$1.05M | -$1.71M |
| Net Income Margin | - | - | - | - |
| Supplementary Data | ||||
| EPS | -0.72 | -0.17 | -0.12 | -0.19 |
| Diluted EPS | -0.72 | -0.17 | -0.12 | -0.19 |
| Weighted Average OS | 8.01M | 9.06M | 9.06M | 9.06M |
| EBITDA | -$4.9M | -$1.52M | -$956K | -$2.13M |
| EBITDA Margin | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $1.24M | $284K | $193K | $154K |
| Short-Term Investments | $3.05M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $4.29M | $284K | $193K | $154K |
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $240K | $56K | $251K | $263K |
| Total Current Assets | $4.86M | $457K | $444K | $417K |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $149K | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $260K | $0 | $0 |
| Total Long-Term Assets | $149K | $260K | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $5M | $717K | $444K | $417K |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $829K | $651K | $655K | $771K |
| Short-Term Debt | $0 | $1.8M | $2.46M | $1.57M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $736K | $632K | $513K | $514K |
| Total Current Liabilities | $2.16M | $3.93M | $4.24M | $3.2M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $73K | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.24M | $3.93M | $4.24M | $3.2M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $20K | $19K | $4K |
| Retained Earnings | -$18.52M | -$12.66M | -$11.13M | -$10.08M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $21.29M | $9.43M | $7.32M | $7.29M |
| Total Equity | $2.77M | -$3.21M | -$3.8M | -$2.79M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $5M | $717K | $444K | $417K |
| Supplementary Data | ||||
| Total Debt | $118K | $1.8M | $2.46M | $1.57M |
| Net Debt | -$1.12M | $1.52M | $2.26M | $1.42M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$5.8M | -$1.55M | -$1M | -$2.15M |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $447K | $10K | $39K | $23K |
| Changes in Working Capital: | ||||
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | $152K | -$5K | -$116K | $150K |
| Other Working Capital | -$616K | $410K | $283K | $327K |
| Total Working Capital Change | -$464K | $405K | $167K | $477K |
| Other Non-Cash Items | $904K | $472K | -$230K | $441K |
| Net Cash from Operating | -$4.92M | -$665K | -$1.03M | -$1.21M |
| Investing Activities | ||||
| Capital Expenditures | -$14K | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 |
| Other Investing Activities | -$3M | $0 | $0 | -$160K |
| Net Cash from Investing | -$3.01M | $0 | $0 | -$160K |
| Financing Activities | ||||
| Debt Repaid | - | - | - | - |
| Common Stock Issuance | $8.48M | $0 | $0 | $3K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$230K | $0 | -$231K |
| Net Cash from Financing | $8.92M | $770K | $1.05M | $1.24M |
| Forex Effect | -$8K | -$4K | $13K | -$10K |
| Net Change in Cash | $980K | $101K | $39K | -$143K |
| Supplementary Data | ||||
| Operating Cash Flow | -$4.92M | -$665K | -$1.03M | -$1.21M |
| Capital Expenditure | -$14K | $0 | $0 | $0 |
| Free Cash Flow | -$4.93M | -$665K | -$1.03M | -$1.21M |
| Cash at Beginning | $311K | $210K | $171K | $314K |
| Cash at End | $1.29M | $311K | $210K | $171K |